NGR-hTNF is a therapeutic agent that acts selectively on tumor blood vessels. It is a recombinant protein formed by combining the antitumor cytokine hTNF (Tumor Necrosis Factor) with a peptide (NGR) that binds a particular CD13 receptor complex located exclusively on the surface of endothelial cells that form the walls of tumor blood vessels. NGR-hTNF can be used in combination with other chemotherapy regimens, allowing them to be more effectively conveyed and enhanced.
For malignant mesothelioma and liver carcinoma, NGR-hTNF has received an orphan drug designation in
both the United States and the European Union.